Article Figures & Data
Figures
- Figure 1.
a, Orthotopic chest wall tumor; b, bilateral pulmonary metastases (line arrows) in mouse thoracic cavity, solid arrow denotes remaining normal lung; c, dorsal surface of chest wall tumor ex vivo; d, parietal pleural surface of chest wall Ewing's sarcoma: solid arrow denotes tumor pushing between the ribs, line arrow denotes spine; e, H&E stain of orthotopic tumor (line arrow) between ribs (solid arrow).
- Figure 2.
a, Solid arrow indicates chest wall tumor 20 days after orthotopic injection of TC71 Ewing's sarcoma cells. No pulmonary metastases were seen in 65% of mice. b, Line arrow indicates early pulmonary metastasis at 18 days after injection of TC71 Ewing's sarcoma cells. No chest wall tumor was seen in 25-30% of mice. Chest wall tumor and pulmonary metastasis at 16 (c) and 22 (d) days post injection (~10% of mice had this phenotype).
- Figure 3.
Lung weights of TC-W (expanded from TC71 lung metastasis) lung metastases compared to normal lung.
- Figure 4.
a, Size of orthotopic chest wall tumors from mice injected with parental cell (TC71, scrambled vector (TC71pd) and PDGFR-β silenced (TC71pdsh) cells; p<0.01. b, Weights of lungs per mouse in TC71 compared to TC71pd and TC-71pdsh inoculated mice; p<0.05.
- Figure 5.
(a-c): Growth comparison of pulmonary metastases 21 days after injection of human Ewing's sarcoma tumor cells into the rib of nude mice. Primary tumor size was statistically significantly smaller in PDGFR-β-silenced ES tumors, TC71pdsh (d-g), compared to control tumors, TC71.
- Figure 6.
a) Western blot of the shRNA PDGFR-B. b) RT-PCR of the shRNA for PDGFR-B.
